The latest food and beverage industry news and trend analysis

QuantiPath, a specialist in rapid pathogen detection and food safety diagnostics, has announced the appointment of Roger Schaller to its Board of Directors. Schaller joins the company with over 30 years of experience in molecular diagnostics, next-generation sequencing, and strategic business development.

The appointment comes as QuantiPath prepares to scale its presence in the global food safety market, leveraging Schaller’s extensive track record of guiding innovative biotech firms toward significant industry outcomes and acquisitions.

Leadership in Molecular Diagnostics

Schaller’s career includes high-level roles at several of the most prominent organisations in the life sciences sector. His previous experience is marked by a pattern of joining firms at critical growth stages and positioning them for acquisition by major industry players.

Key highlights of Schaller’s professional background include:

• Cepheid: Served as Director of Sales and Marketing and Senior Director of Business Development, where he assisted in the global adoption of the company’s PCR-based infectious disease detection platform before its acquisition by Danaher.

• Affymetrix and RainDance Technologies: Held senior leadership positions at these firms, which were later acquired by Life Technologies and Bio-Rad, respectively.

• Executive Leadership: Has served as COO, CCO, and CEO for multiple startups, and most recently held the role of Vice President of Business Development at seqWell.

Currently, Schaller acts as an Executive Advisor for BioNex Solutions, bringing a broad perspective on automation and biotech assay provision to the QuantiPath board.

Advancing the GenoPATHX Food Safety Platform

The addition of Schaller to the board is timed to support the market entry of QuantiPath’s next generation of multiplex qPCR testing. The company’s primary focus is the GenoPATHX platform, which aims to provide faster and more accurate pathogen detection within the food supply chain.

The rollout begins with a multiplex Salmonella assay, a critical tool for food producers facing increasing regulatory and consumer pressure to ensure product safety. John LoPorto, CEO of QuantiPath, stated that Schaller’s relationships across the diagnostics and food safety industries, combined with his strategic instincts, are essential for guiding the company as it advances this platform.

Market Positioning and Commercial Scale

Schaller’s role on the board will involve applying his commercial and technical expertise to help the QuantiPath team scale its operations and establish strategic partnerships. The company’s mission is centred on addressing food safety as a global priority through improved diagnostic technology.

The food safety industry continues to seek rapid, high-sensitivity testing solutions that can be integrated into existing supply chain workflows. Schaller noted that the introduction of multiplex qPCR testing represents an important shift in the market, allowing for more comprehensive screening in a single test format.

With this appointment, QuantiPath strengthens the leadership driving its commercial strategy, focusing on delivering faster diagnostic results to minimise risk and contribute to a more resilient global food supply.